Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NBIX 
Neurocrine Biosciences Inc (NBIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NBIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -18.66% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.80B USD | Price to earnings Ratio 33.02 | 1Y Target Price 163.57 |
Price to earnings Ratio 33.02 | 1Y Target Price 163.57 | ||
Volume (30-day avg) 1280308 | Beta 0.35 | 52 Weeks Range 105.17 - 157.98 | Updated Date 04/2/2025 |
52 Weeks Range 105.17 - 157.98 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.49% | Operating Margin (TTM) 20.87% |
Management Effectiveness
Return on Assets (TTM) 10.46% | Return on Equity (TTM) 14.16% |
Valuation
Trailing PE 33.02 | Forward PE 21.55 | Enterprise Value 10047277389 | Price to Sales(TTM) 4.58 |
Enterprise Value 10047277389 | Price to Sales(TTM) 4.58 | ||
Enterprise Value to Revenue 4.27 | Enterprise Value to EBITDA 15.71 | Shares Outstanding 99703504 | Shares Floating 98515061 |
Shares Outstanding 99703504 | Shares Floating 98515061 | ||
Percent Insiders 1.02 | Percent Institutions 98.07 |
Analyst Ratings
Rating 4.46 | Target Price 167.67 | Buy 5 | Strong Buy 15 |
Buy 5 | Strong Buy 15 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Neurocrine Biosciences Inc
Company Overview
History and Background
Neurocrine Biosciences, founded in 1992, is a biopharmaceutical company focused on neurological and endocrine-related disorders. It has evolved from a research-focused organization to a commercial enterprise with FDA-approved products.
Core Business Areas
- Neurology: Development and commercialization of therapies for neurological disorders, including movement disorders like tardive dyskinesia and Parkinson's disease.
- Endocrinology: Development and commercialization of therapies for endocrine-related disorders, focusing on women's health and reproductive health.
Leadership and Structure
The leadership team includes Kevin C. Gorman (CEO) and other key executives. The company has a functional organizational structure with departments dedicated to research, development, commercialization, and support functions.
Top Products and Market Share
Key Offerings
- INGREZZA (valbenazine): INGREZZA is used for the treatment of tardive dyskinesia. It has a significant market share in the TD treatment market. It has achieved substantial revenue growth. Competitors include Teva Pharmaceutical and AbbVie, though INGREZZA is the market leader.
- ORILISSA (elagolix): ORILISSA is used for the management of endometriosis-associated pain. Market share is growing but faces competition. The primary competitor is AbbVie and Myovant Sciences with other GnRH antagonists and pain management solutions. Revenue from Orilissa has been inconsistent, with some periods of growth followed by declines.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Demand is driven by aging populations, chronic diseases, and technological advances.
Positioning
Neurocrine Biosciences is positioned as an innovative company focusing on specialized neurological and endocrine disorders. Its competitive advantages include its expertise in drug development and commercialization, its established sales force, and its strong intellectual property portfolio.
Total Addressable Market (TAM)
The TAM for Neurocrine's products spans several billion dollars across tardive dyskinesia, endometriosis, and other targeted indications. Neurocrine is positioned to capture a significant portion of this TAM through continued commercialization and pipeline development.
Upturn SWOT Analysis
Strengths
- FDA-approved products with market exclusivity
- Strong research and development capabilities
- Established sales and marketing infrastructure
- Experienced management team
- Robust pipeline of drug candidates
Weaknesses
- Reliance on a few key products
- High dependence on successful clinical trials
- Potential for generic competition upon patent expiration
- High research and development costs
- Reimbursement challenges from payers
Opportunities
- Expansion into new therapeutic areas
- Partnerships and collaborations with other companies
- Acquisition of complementary technologies or products
- Geographic expansion into international markets
- Development of new formulations or delivery methods
Threats
- Competition from other pharmaceutical companies
- Regulatory changes and increased scrutiny
- Failure of clinical trials
- Patent challenges and loss of exclusivity
- Economic downturn and reduced healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- TEVA
- MYOV
Competitive Landscape
Neurocrine has an advantage in the tardive dyskinesia market with INGREZZA. AbbVie and Myovant are stronger in the endometriosis market. Competition is intense, requiring innovation and effective marketing.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Neurocrine Biosciences has experienced substantial revenue growth driven by the commercial success of INGREZZA. However, growth has been impacted by competitive pressures and market dynamics in the endometriosis market.
Future Projections: Analysts project continued revenue growth for Neurocrine Biosciences driven by INGREZZA and potential new product launches. However, growth projections depend on the success of ongoing clinical trials and market acceptance of new products.
Recent Initiatives: Recent initiatives include expanding the INGREZZA label, developing new therapies for neurological and endocrine disorders, and strengthening its commercial infrastructure.
Summary
Neurocrine Biosciences demonstrates strong growth potential mainly driven by INGREZZA. The company's robust pipeline and strategic initiatives present solid opportunities for expansion. It faces competition from other pharmaceutical companies, which needs consideration. Additionally, the company must focus on successful clinical trials for future growth and revenue.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurocrine Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1996-05-23 | CEO & Director Mr. Kyle W. Gano Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1800 | Website https://www.neurocrine.com |
Full time employees 1800 | Website https://www.neurocrine.com | ||
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.